Abstract
In N-methyl-D-aspartate receptor (NMDAR) antibody encephalitis, NMDAR-autoantibodies are hypothesised to cause prominent neuropsychiatric symptoms by internalizing NMDARs. However, supporting evidence comes chiefly from in vitro and rodent data with scant direct evidence from affected humans. Here, we used in vivo positron emission tomography (PET) with [18F]GE-179 to show a mean 30% reduction of the density of open, activated NMDARs in grey matter of persistently NMDAR-autoantibody seropositive patients following NMDAR-antibody encephalitis compared to healthy controls. The reduction was most prominent in the anterior temporal and superior parietal cortices. These patients had normal structural MRIs and mild residual symptoms. In contrast, one symptom-free patient who recovered from NMDAR-antibody encephalitis and was not NMDAR-autoantibody seropositive had normal density of active NMDARs. These findings reveal a functional deficit of open, activated NMDARs in humans with NMDAR-autoantibodies. Moreover, we observed a functional NMDAR deficit for up to 8 months following the disease peak, despite only mild residual symptoms, highlighting the considerable compensatory capacity of the human brain.
One Sentence Summary Reductions of activated NMDA receptors detected in vivo in female patients following NMDA-receptor-antibody encephalitis.
Competing Interest Statement
MG reports fees from Advisis, Arvelle, Bial, Eisai, Nestle Health Science, and UCB outside the submitted work. IJ has received honoraria/consultancy/research support from Biogen Idec, Merck, Neuway, and Sanofi Genzyme, all outside the submitted work. CJM has received fees from GE Healthcare Ltd but neither he nor any of his family have ever been employed by the organisation; nor does he or any of his family have holdings or a financial stake in GE Healthcare Ltd. SRI is a coapplicant and receives royalties on patent application WO/210/046716 (U.K. patent no., PCT/GB2009/051441) entitled Neurological Autoimmune Disorders (licensed for the development of assays for LGI1 and other VGKC-complex antibodies) and Diagnostic Strategy to improve specificity of CASPR2 antibody detection. (Ref. JA94536P.GBA; PCT/G82019 /051257). SRI has received honoraria/consultancy/research support from UCB, Immunovant, MedImmun, ADC therapeutics, CSL Behring, and ONO Pharma. KS is funded by Mallinckrodt Pharmaceuticals. EÅ collaborates with Cerveau Technologies on unrelated studies. MCW reports a grant from Vitaflo and personal fees from UCB Pharma, Eisai, Sage and Marinus outside the submitted work.
Funding Statement
This work has been funded by an MRC PET Neuroscience programme grant (Training and Novel Probes Programme in PET Neurochemistry MR/K02308X/1) and by an MRC Developmental Pathway Funding Scheme grant (MR/L013215/1).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
NRES Committee London - Stanmore gave ethical approval for this work, IRAS project ID 178193
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Full list of NEST Investigators is given in the online supplement.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
